Malignant Solid Tumor
Conditions
Brief summary
The purpose of this study is to prospectively validate treatment benefit of an individualized treatment concept based on molecular profiling (MP) from paraffin-embedded tumor tissue sections obtained before the start of treatment (real time biopsy).
Detailed description
The treatment concept will be considered to be of clinical benefit for the individual patient if a progression-free survival (PFS) ratio (PFS on MP-based therapy / best PFS achieved by prior therapy) will be \> 1.0 thus generating a patient cohort with this very property. Thereby, the null hypothesis (that ≤ 40 % of this patient population would have a PFS ratio of \> 1.0) will be evaluated with each patient being his own control. For tumor types with high numbers of patients per cohort, the overall response rate (ORR) will be evaluated.
Interventions
OTHERindividual therapy
Patient will be treated with individual therapy.
Sponsors
Medical University of Vienna
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
Consenting patients of \>19 years with advanced cancer fulfilling the criteria of having: * an advanced malignancy with metastatic spread refractory to conventional treatment * a life expectancy of \>4 months, * the possibility to access and biopsy tumour material within 4 weeks before onset of individualized treatment, * a malignancy amenable to further treatment options with either cytotoxic drugs, tyrosine kinase inhibitors, monoclonal antibodies or related molecules with anti-proliferative potential to cancer cells, as assessed by the ex vivo analysis and a likelihood of treatment response according to the mathematical model (all outlined in detail above), * agreed to participate by their signature on an informed consent form are eligible.
Exclusion criteria
* Presence of further treatment options, as defined by NCCN guidelines which are available in Austria representing a possible further treatment-related response by conventional therapies according to generally accepted medical evidence. * No fresh and viable tumor material available. * Current use of therapeutic warfarin. * Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia. * Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. * A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. * A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency. * History of other malignancy. Subjects who have been disease-free for 5 years or those with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. * Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol) * unwillingness or inability to follow the procedures required in the protocol. * pregnant or lactating females. * History of alcohol or drug abuse within 6 months prior to screening. * No informed consent available.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Use of real time biopsy to establish an individual molecular profile by using next generation sequencing | 2 years | pathological examination (includes genetic and target expression profiling, and drug sensitivity screening) to rank treatment options and the potential correlation between treatment response and progression free survival |
Countries
Austria
Outcome results
None listed